Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
GAITHERSBURG, Md., March 31, 2017 -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) to manufacture and store bulk drug substance for its botulism antitoxin, BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)], valued at approximately $53 million with a five-year period of performance. This modification to the contract will enable future filling and deliveries of final drug product to the Strategic National Stockpile (SNS). BAT is indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients.
“Emergent is proud to be a longstanding partner to the U.S. government in providing first-in-class and only-in-class products that address biological threat agents,” said Adam Havey, executive vice president, business operations at Emergent BioSolutions. “This modification to the contract represents the U.S. government’s continued commitment to developing critical countermeasures such as BAT that address public health threats and fulfill its preparedness needs.”
Emergent has been supplying BAT to the SNS under contract HHSO100200600017C, which was signed in 2006 with BARDA, within the Office of the Assistant Secretary for Preparedness and Response, in the U.S. Department of Health and Human Services. BAT is the only botulism antitoxin licensed by the U.S. Food and Drug Administration and distributed from the Centers for Disease Control and Prevention for treating naturally occurring, non-infant botulism, and for administration under emergency conditions.
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3281 [email protected]
